Acorda Therapeutics, Inc.
NASDAQ:ACOR
0.66 (USD) • At close April 11, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Acorda Therapeutics, Inc. |
Symbool | ACOR |
Munteenheid | USD |
Prijs | 0.661 |
Beurswaarde | 821,028 |
Dividendpercentage | 0% |
52-weken bereik | 0.612 - 24.2 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. Ron Cohen M.D. |
Website | https://www.acorda.com |
An error occurred while fetching data.
Over Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)